Trial Outcomes & Findings for Can We Miss Pigmented Lesions in Psoriasis Patients? (NCT NCT01053819)
NCT ID: NCT01053819
Last Updated: 2018-02-23
Results Overview
Recruitment status
COMPLETED
Study phase
PHASE4
Target enrollment
6 participants
Primary outcome timeframe
Patients will complete study within 6 months.
Results posted on
2018-02-23
Participant Flow
Participant milestones
| Measure |
Etanercept
Patients will receive six months of treatment with Enbrel 50mg SC given twice a week for the first three months and 50 mg once a week thereafter.
|
|---|---|
|
Overall Study
STARTED
|
6
|
|
Overall Study
COMPLETED
|
6
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Can We Miss Pigmented Lesions in Psoriasis Patients?
Baseline characteristics by cohort
| Measure |
Etanercept
n=6 Participants
open label treatment per FDA approval for 24 weeks
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
6 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
4 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
2 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
6 participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Patients will complete study within 6 months.Population: The data for this Outcome was not collected and due to the length of time, the records have been destroyed.
Outcome measures
| Measure |
Etanercept
n=6 Participants
open label treatment per FDA approval for 24 weeks
|
|---|---|
|
The Primary Endpoint for This Study Will be a Change From Baseline in the Number of Pigmented Lesions on Skin Previously Covered by Psoriatic Plaques.
|
0 participants
|
SECONDARY outcome
Timeframe: Patients will complete the study within 6 monthsPopulation: The data for this Outcome was not collected and due to the length of time, the records have been destroyed.
The data for this Outcome was not collected and due to the length of time, the records have been destroyed.
Outcome measures
Outcome data not reported
Adverse Events
Etanercept
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place